These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2679628)

  • 1. Immunotherapy in type 1 diabetes: present status.
    Pozzilli P; Kolb H
    Immunol Today; 1989 Oct; 10(10):321-2. PubMed ID: 2679628
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune intervention with anti-CD3 in diabetes.
    Harlan DM; von Herrath M
    Nat Med; 2005 Jul; 11(7):716-8. PubMed ID: 16015359
    [No Abstract]   [Full Text] [Related]  

  • 3. Early intervention in insulin-dependent diabetes mellitus.
    Cahill GF
    Curr Probl Clin Biochem; 1983; 12():108-18. PubMed ID: 6418442
    [No Abstract]   [Full Text] [Related]  

  • 4. [Does the current knowledge on the pathogenesis of type 1 diabetes justify immunotherapeutic intervention?].
    Pozzilli P; Signore A; Andreani D
    Recenti Prog Med; 1986 May; 77(5):245-8. PubMed ID: 3526461
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunotherapy in pre-type 1 diabetes mellitus.
    Bach JF; Dupré J; Eisenbarth GS; Harrison LC; Maclaren NK; Nerup J; Pozzilli P
    Diabetologia; 1990 Dec; 33(12):741. PubMed ID: 2073989
    [No Abstract]   [Full Text] [Related]  

  • 6. [Immunological disorder in diabetes mellitus].
    Takeuchi K; Jodo S; Koike T
    Nihon Rinsho; 1997 Oct; 55 Suppl():700-4. PubMed ID: 9392184
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical review 17: Immunotherapy of type I diabetes mellitus.
    Marks JB; Skyler JS
    J Clin Endocrinol Metab; 1991 Jan; 72(1):3-9. PubMed ID: 1986025
    [No Abstract]   [Full Text] [Related]  

  • 8. [Type I diabetes mellitus: immunopathogenesis and chances of primary immunotherapy].
    Ziegler AG; Standl E
    Med Klin (Munich); 1987 Oct; 82(22):796-800. PubMed ID: 3316970
    [No Abstract]   [Full Text] [Related]  

  • 9. The pathogenesis, prediction, and prevention of insulin-dependent diabetes mellitus.
    Muir A; Schatz DA; Maclaren NK
    Endocrinol Metab Clin North Am; 1992 Jun; 21(2):199-219. PubMed ID: 1612064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of self-tolerance is a feasible approach to control ongoing beta-cell specific autoreactivity: its relevance for treatment in established diabetes and islet transplantation.
    Chatenoud L
    Diabetologia; 2001 May; 44(5):521-36. PubMed ID: 11380070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunogenetics and new therapies in type I diabetes mellitus].
    Gannage-Yared MH
    J Med Liban; 1999; 47(2):139-43. PubMed ID: 10410471
    [No Abstract]   [Full Text] [Related]  

  • 12. [Immuno- and regeneration therapy of recently diagnosed diabetes mellitus type I].
    Huth E
    Klin Padiatr; 1985; 197(2):75-84. PubMed ID: 3157826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunology of type-1 diabetes. The initial stages in a causal therapy].
    Scherbaum WA; Hedderich U; Pfeiffer EF
    Dtsch Med Wochenschr; 1986 Apr; 111(15):593-6. PubMed ID: 3514198
    [No Abstract]   [Full Text] [Related]  

  • 14. Specific immunotherapy in insulin-dependent diabetes mellitus (preliminary report).
    Lohmann D; Bierwolf B; Krug J; Lampeter E; Verlohren HJ
    Exp Clin Endocrinol; 1986 Aug; 87(3):333-6. PubMed ID: 3536537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for insulin-dependent diabetics?
    Rossini AA
    N Engl J Med; 1983 Feb; 308(6):333-5. PubMed ID: 6337326
    [No Abstract]   [Full Text] [Related]  

  • 16. [Etiology and pathogenesis of type I diabetes].
    Ziegler AG
    Z Gesamte Inn Med; 1993 Mar; 48(3):100-7. PubMed ID: 8475631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Type 1 diabetes mellitus and immunopathology].
    Koike T
    Nihon Rinsho; 2002 Jul; 60 Suppl 7():399-406. PubMed ID: 12238080
    [No Abstract]   [Full Text] [Related]  

  • 18. Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes.
    Sutherland DE; Sibley R; Xu XZ; Michael A; Srikanta AM; Taub F; Najarian J; Goetz FC
    Trans Assoc Am Physicians; 1984; 97():80-7. PubMed ID: 6398950
    [No Abstract]   [Full Text] [Related]  

  • 19. Nicotinamide: potential for the prevention of type 1 diabetes?
    Gale EA
    Horm Metab Res; 1996 Jul; 28(7):361-4. PubMed ID: 8858387
    [No Abstract]   [Full Text] [Related]  

  • 20. Low-dose IL-2 as a therapeutic agent for tolerance induction.
    Malek TR; Pugliese A
    Immunotherapy; 2011 Nov; 3(11):1281-4. PubMed ID: 22053878
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.